Evidence map›Paper›PMID 42350984›Full record

ArticleBMC infectious diseases2026

Trends in methicillin-resistant Staphylococcus aureus detection-rates and antibiotic resistance profiles in a cancer hospital from 2015 to 2024.

Hui Wang, Qin Huang, Qingqing Tian, Weiwei Yang, Anran Liu, Jiayang Tang, Hailin Zhang, Chunlin Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hui WangSichuan Clinical Research Center for Cancer, Sichuan Cancer Center, The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China.
Qin HuangSichuan Clinical Research Center for Cancer, Sichuan Cancer Center, The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China.
Qingqing TianSichuan Clinical Research Center for Cancer, Sichuan Cancer Center, The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China.
Weiwei YangSichuan Clinical Research Center for Cancer, Sichuan Cancer Center, The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China.
Anran LiuSichuan Clinical Research Center for Cancer, Sichuan Cancer Center, The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China.
Jiayang TangSichuan Clinical Research Center for Cancer, Sichuan Cancer Center, The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China.
Hailin ZhangSichuan Clinical Research Center for Cancer, Sichuan Cancer Center, The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China.
Chunlin WuSichuan Clinical Research Center for Cancer, Sichuan Cancer Center, The Department of Hospital Infection Control and Public Health, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China. wuchunlin@scszlyy.org.cn.

Funding

Sichuan Provincial Medical Association's project on the Young Medical Scientists of Sichuan Provincial innovation Q22036
6 · The paper itself

Abstract

backgroundMethicillin-resistant Staphylococcus aureus (MRSA) is an important antimicrobial-resistant organism in healthcare settings, and long-term surveillance is important for infection prevention and antimicrobial stewardship. Long-term epidemiological data on MRSA remain limited, particularly in cancer specialty hospitals. This study aimed to investigate the distribution and antimicrobial resistance trends of MRSA in a cancer hospital over a ten-year period (2015-2024).

methodsWe analyzed data from clinical isolates obtained at Sichuan Cancer Hospital between 2015 and 2024. Patient demographics, departmental sources, specimen information, hospital-acquired infection classification, and antimicrobial susceptibility testing results were collected. The epidemiological distribution and temporal trends in MRSA resistance were assessed over the study period.

resultsAmong 13,829 hospitalization records with at least one positive culture, 1,550 Staphylococcus aureus isolates were identified. Of these, 433 were identified as MRSA (detection rate 27.94%). The MRSA detection rate initially increased, peaked at 35.48% in 2018, and then gradually declined; however, the interannual variations were not statistically significant. MRSA was detected across 23 departments. The highest number of MRSA isolates was detected in Surgery, particularly Head and Neck Surgery (54 isolates, 12.47%), followed by Radiotherapy, Internal Medicine, and other departments. Among MRSA detections classified as hospital-acquired infections, the largest number occurred in Head and Neck Surgery (31 cases, 20.95%). The Head and Neck Radiotherapy Ward and Thoracic Surgery Ward also had relatively high numbers of MRSA-associated hospital-acquired infections. The main infection sites among MRSA-associated hospital-acquired infections were the lower respiratory tract (60 cases, 40.54%) and surgical sites (32 cases, 21.62%). Regarding antimicrobial resistance, the resistance rates of MRSA to most tested antimicrobial agents did not show a clear increasing or decreasing trend. MRSA remained fully susceptible to daptomycin, linezolid, tigecycline, and vancomycin (all with 0% resistance). Exploratory analyses showed interannual differences in resistance rates for erythromycin, chloramphenicol, and moxifloxacin, but these findings should be interpreted cautiously.

conclusionThis ten-year surveillance study in a cancer specialty hospital showed an average MRSA detection rate of 27.94%, with departmental heterogeneity in MRSA detection and in MRSA-associated hospital-acquired infections. Head and Neck Surgery accounted for the largest number of MRSA-associated hospital-acquired infections, whereas the Neurosurgery Ward had the highest MRSA detection rate. Antimicrobial susceptibility testing showed that resistance rates of MRSA to most agents remained stable. These findings may inform local empirical therapy, antimicrobial stewardship, and department-specific infection prevention strategies, but they should not be interpreted as direct evidence for individualized treatment decisions. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Anti-Bacterial AgentsCancer Care FacilitiesCross InfectionMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAdultAgedAged, 80 and overChinaFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedAnti-Bacterial AgentsAntimicrobial agentsDrug resistanceEpidemiologyMRSA

Identifiers

PMID42350984
PMCPMC13412135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.